| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total revenues for the third quarter 2026 increased 6% to $73.7 billion |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure
Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned where health care costs are concentrating with multiple avenues for growth |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Total revenues for the second quarter 2026 increased 7% to $71.7 billion |
| 13 May 2026 |
8-K: Regulation FD Disclosure
The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2026 consolidated adj... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Total revenues for the first quarter 2026 increased 5% to $68.5 billion |
| 27 Apr 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Cigna Group held its Annual Meeting of Shareholders on April 22, 2026 (the “Annual Meeting”). Of the 263,660,761 shares outstanding and entitled to vote, 237,225,441 shares, or 89.97%, were represented in person or by proxy at the An... |
| 03 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of Directors |
| 27 Feb 2026 |
8-K: Regulation FD Disclosure
The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2026 consolidated adj... |
| 05 Feb 2026 |
8-K: Results of Operations and Financial Condition
Shareholders’ net income for 2025 was $6.0 billion, or $22.18 per share |
| 18 Nov 2025 |
8-K: Other Events
On October 22, 2025, the Board of Directors (the “Board”) of The Cigna Group (the “Company”) approved changes to the Board’s committee structure, effective January 1, 2026 (the “Effective Date”). Recognizing and responding to the dynamic... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
Total revenues for the third quarter 2025 increased 10% to $69.7 billion |
| 20 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
THIS SUPPLEMENTAL INDENTURE NO. 8, dated as of September 4, 2025 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK T... |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure
The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2025 consolidated adj... |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
Total revenues for the second quarter 2025 increased 11% to $67.2 billion |
| 02 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
BLOOMFIELD, Conn., June 2, 2025 – Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. |
| 20 May 2025 |
8-K: Regulation FD Disclosure
The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2025 consolidated adj... |
| 02 May 2025 |
8-K: Results of Operations and Financial Condition
BLOOMFIELD, CT, May 2, 2025 – Global health company The Cigna Group (NYSE: CI) today reported strong first quarter 2025 results, reflecting growth and focused execution across its diversified portfolio of businesses. |
| 28 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
On April 24, 2025, The Cigna Group (the “Company”) entered into a $6.5 billion Revolving Credit and Letter of Credit Agreement with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, and BofA Securities, Inc., C... |
Loading...